Discover 1,705 paid clinical trials in Detroit, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,705
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Detroit MI, Hilliard OH, Pittsburgh PA, Morgantown WV,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Location: Detroit MI, Clinton Township MI, Ann Arbor MI,
Sponsor: 89bio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06419374
Phase3, Recruiting
Featured
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
for
Non Small Cell Lung Carcinoma
Location: Detroit MI, Fort Wayne IN, Columbus OH, Hinsdale IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06772623
Phase1, Phase2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
for
Metastatic Breast Cancer
Location: Detroit MI, Toronto, Hyattsville MD, Washington D.C. DC,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT05894239
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
for
Idiopathic Pulmonary Fibrosis
Location: Detroit MI, Ann Arbor MI, Champaign IL, Falls Church VA,
Sponsor: AbbVie
Sex: All
Age: 40+
Code: NCT07230288
Phase2, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Detroit MI, Cleveland OH, Mayfield Heights OH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase3, Recruiting
Featured
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
for
Neovascular Age-related Macular Degeneration
Location: Royal Oak MI, Cleveland OH, Erie PA, Dublin OH,
Sponsor: AbbVie
Sex: All
Age: 50+
Code: NCT07007065
Phase3, Recruiting
Featured
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
for
Early Breast Cancer
Location: Sterling Heights MI, Fountain Valley CA
Sponsor: Genentech, Inc.
Sex: Female
Age: 18+
Code: NCT07541079
Phase3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Location: Chesterfield MI, Westlake OH, London, Akron OH, Lima OH,
Sponsor: 89bio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06318169
Phase3, Recruiting
Featured
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
for
Chronic Migraine
Location: Ann Arbor MI, London, Amherst NY, Scottdale PA,
Sponsor: AbbVie
Sex: All
Age: 12 - 17
Code: NCT06810505
Phase3, Recruiting
Featured
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Ann Arbor MI, London, Amherst NY, Cincinnati OH,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase3, Recruiting
Featured
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
for
Lymphoma
Location: Ann Arbor MI, London, Toronto, Morgantown WV,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06084936
Phase3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
for
Multiple Myeloma
Location: Ann Arbor MI, Winston-Salem NC, New York NY,